Zhong Nanshan’s “roll call” Banlangen Baiyunshan a + H stock market value soared more than 10 billion yuan

Zhong Nanshan’s Banlangen products were “named”. On Friday, the A-share limit of Baiyunshan was up, and the H-share was up 13.28%. The market value of the company soared by 10 billion yuan a day!

just released the novel coronavirus announcement by Baiyun Mountain, saying that the relevant conclusions in the media reports are only for the experimental results of the in vitro screening of the new type coronavirus launched by Fufang Banlangen Keli and Huang company of the joint venture company. Further work will be carried out in the future, and there is still some uncertainty in the relevant work. The sales of compound Banlangen Granules are not expected to have a significant impact on the company’s operating performance. < p > < p > the official micro blog of Baiyunshan recently announced that Zhong Nanshan, an academician of the Chinese Academy of engineering, said at a seminar recently that Baiyunshan compound Banlangen Granules are effective against new coronavirus. On October 16, many media reported this. It is reported that academician Zhong Nanshan mentioned in his report at the seminar that day that, after more than ten years of joint research, Radix Isatidis of Baiyunshan can prevent virus from entering cells and has anti-inflammatory effect, that is, Radix Isatidis has pharmacological effects such as inhibiting virus invasion and regulating inflammation. Since the novel coronavirus pneumonia outbreak, novel coronavirus has been studied by the research team. Combined with the beneficial experience of clinical practice, the research team has worked with Guangyao group to screen 16 new proprietary Chinese medicines from 10 enterprises in China. The results showed that Fufang Banlangen Keli had the inhibitory effect in vitro. < / P > < p > the strong performance of Baiyunshan also led to the trend of anti influenza concept stocks on that day. The trading limit of Xiangxue pharmaceutical and Xinguang Pharmaceutical Co., Ltd., HongRi Pharmaceutical Co., Ltd. rose by more than 8%, sunflower Pharmaceutical Co., Ltd. and cucurbitaco co Co., Ltd. rose by more than 7%. According to the clarification announcement issued by Baiyunshan on October 18, the company was concerned about the reports on the in vitro research results of Baiyunshan compound Banlangen Granules in some media recently. In this regard, the company said that Guangzhou Baiyunshan Hutchison Huangpu traditional Chinese Medicine Co., Ltd. (hereinafter referred to as “Baiyunshan and Huangpu company”) is a joint venture with 50% of the company’s shares, which is not included in the scope of merger of the company. The company adopts the equity method of long-term equity investment for accounting. The company mainly engaged in the production and sales of Chinese patent medicine and drug research and development, the main products include Banlangen Granules, compound Danshen tablets, compound Banlangen Granules, etc.

Baiyun Mountain said that novel coronavirus in the laboratory was selected by Zhong Nanshan academician team for the purpose of screening the new type of coronavirus in Fufang Banlangen Keli and the Yellow company. The follow-up work needs further work on this product. The announcement also introduces the current domestic market situation of Banlangen products. According to the announcement, at present, Banlangen products are fully competitive products in the domestic market. There are a large number of approved document numbers for Banlangen Granules and compound Banlangen Granules. Banlangen products are not the exclusive products of the company or its affiliated enterprises. According to the announcement, there are 981 approval numbers and 147 approval numbers for Banlangen Granules and compound Banlangen Granules, respectively. In 2019, the sales volume of domestic urban retail drugstores will be 1.065 billion yuan and 430 million yuan respectively. Both products have the effect of clearing away heat, detoxification and cooling blood. According to the public data, Baiyunshan is mainly engaged in the research and development, manufacturing and sales of traditional Chinese and Western patent medicines, chemical raw materials, natural drugs, biological medicine and chemical raw material drug intermediates, as well as the R & D, production and sales of big health products. It has 12 time-honored pharmaceutical factories, such as Chen Liji pharmaceutical factory, Zhongyi Pharmaceutical Co., Ltd., pan Gaoshou Pharmaceutical Co., Ltd., etc. in addition, “Wang Laoji” and “Baiyunshan” brands are also well-known. In view of the impact of Banlangen products on the performance of listed companies, Baiyunshan said that at present, only Baiyunshan and Huang companies produce and sell Banlangen products among the company, its subsidiary companies and joint ventures. < / P > < p > in 2019, the company’s investment income from Baiyunshan and Huanghe company was RMB 67.9603 million, accounting for 1.65% of the company’s total profit of the year; in the first half of 2020, the investment income was RMB 35.9982 million, accounting for 1.59% of the total profit of the company in the current period. < / P > < p > the sales revenue of compound Banlangen Granules produced by Baiyunshan and Huang company in 2019 is about 109.1007 million yuan, accounting for 7.23% of the company’s sales revenue in that year; the sales revenue in the first half of 2020 is about 75.5461 million yuan, accounting for 8.35% of the company’s sales revenue in the same period. The sales of compound Banlangen Granules are not expected to have a significant impact on the company’s operating performance. It is worth mentioning that in the first half of this year, the performance of Baiyunshan is not ideal. The semi annual report shows that in the first half of 2020, the company’s operating revenue was 30.47 billion yuan, a year-on-year decrease of 8.61%; the net profit attributable to the company’s shareholders was 1.764 billion yuan, a year-on-year decrease of 30.75%. Novel coronavirus pneumonia outbreak and impact in the first half of 2020,

group said that the business segments of the group were affected to varying degrees, resulting in a year-on-year decline in operating performance. < / P > < p > Disclaimer: the purpose of this article reprinted by china.com finance and economics is to convey more information and does not represent the views and positions of the website. The content of this paper is for reference only and does not constitute investment advice. Investors operate accordingly and bear their own risks. < p > < p > Chinanet is a national key news website under the leadership of the Information Office of the State Council and managed by China foreign language publishing and Distribution Bureau. Through 11 versions in 10 languages, the website releases information 24 hours a day, which is an important window for China to carry out international communication and information exchange.